Otuska Pharmaceutical completed the acquisition of Visterra for $430m.

Otuska Pharmaceutical, a global healthcare company, completed the acquisition of Visterra, a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for $430m. "This transaction affirms the power of Visterra's novel technology platform, the promise of our product candidates, and the value our employees and shareholders have created. Our two companies share a common culture of creativity and innovation, and commitment to patients with kidney diseases, cancer and other hard-to-treat diseases. Joining forces with Otsuka will provide Visterra the resources, support and commitment to accelerate development of our pipeline and fully realize the potential of our technology platform," Brian J. G. Pereira, Visterra CEO.